BRIEF-AstraZeneca Says Enhertu Delayed Disease Progression In DESTINY-Breast02 Phase III Trial

PHYSICIAN'S CHOICE OF TREATMENT IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER * ASTRAZENECA - PHASE III TRIAL VERSUS. PHYSICIAN'S CHOICE OF TREATMENT IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER * ASTRAZENECA: RESULTS CONSISTENT WITH PREVIOUS TRIALS, REINFORCING BENEFIT OF ASTRAZENECA AND DAIICHI SANKYO'S ENHERTU IN PREVIOUSLY TREATED PATIENTS Source text for Eikon: Further company coverage:

AstraZeneca PLC: * ASTRAZENECA: ENHERTU SIGNIFICANTLY DELAYED DISEASE PROGRESSION IN DESTINY-BREAST02

* ASTRAZENECA PLC - ENHERTU IMPROVED PFS IN MBC IN DESTINY-BREAST02 * ASTRAZENECA: PHASE III TRIAL VERSUS. PHYSICIAN'S CHOICE OF TREATMENT IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER

* ASTRAZENECA - PHASE III TRIAL VERSUS. PHYSICIAN'S CHOICE OF TREATMENT IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER * ASTRAZENECA: RESULTS CONSISTENT WITH PREVIOUS TRIALS, REINFORCING BENEFIT OF ASTRAZENECA AND DAIICHI SANKYO'S ENHERTU IN PREVIOUSLY TREATED PATIENTS Source text for Eikon: Further company coverage: